Multiple Sclerosis and Related Disorders, Год журнала: 2024, Номер 83, С. 105457 - 105457
Опубликована: Янв. 19, 2024
Язык: Английский
Multiple Sclerosis and Related Disorders, Год журнала: 2024, Номер 83, С. 105457 - 105457
Опубликована: Янв. 19, 2024
Язык: Английский
Multiple Sclerosis and Related Disorders, Год журнала: 2024, Номер 87, С. 105636 - 105636
Опубликована: Апрель 17, 2024
Язык: Английский
Процитировано
6Multiple Sclerosis and Related Disorders, Год журнала: 2024, Номер 86, С. 105615 - 105615
Опубликована: Апрель 8, 2024
Fatigue and disability are indicators of disease progression experienced by many people with multiple sclerosis (pwMS). Understanding trajectories these outcomes, their predictors, may provide insight to potential interventions for MS management.
Язык: Английский
Процитировано
3Multiple Sclerosis Journal - Experimental Translational and Clinical, Год журнала: 2025, Номер 11(2)
Опубликована: Апрель 1, 2025
Background Innovations are essential to meet the needs of people with MS (PwMS), particularly in addressing delays diagnosis and treatment, supporting patient self-management. Objectives To evaluate real-world use outcomes digital technologies holistic management strategies for at a UK Centre. Methods Digital tools PwMS included Patients Know Best (a personal health record) CONNECTPlus ® (an educational app). Tools healthcare professionals Infoflex clinical database MSProDiscuss assessing disease progression). A Healthy Lifestyle Clinic was introduced promote brain health. The impact these interventions on time-to-diagnosis, time-to-disease-modifying therapy (DMT) initiation, non-elective admissions, hospital costs evaluated retrospectively from 2018 2023, comparing pre-intervention (2018–2019) post-intervention (2020–2023) periods, while accounting separately COVID-19 years (2020–2021). Results Trends indicated higher likelihood progression patients delayed (p < 0.001), reduction time DMT an average 23.5 5.8 months = 0.024), post-MS implementation. Non-elective admissions also decreased compared neighbouring hospitals. Conclusions were associated positive trends care delivery. Further research is needed validate findings.
Язык: Английский
Процитировано
0European Journal of Neurology, Год журнала: 2024, Номер 31(10)
Опубликована: Авг. 7, 2024
Healthy lifestyle behaviour modification may improve health outcomes in people with multiple sclerosis (pwMS), but empirical evidence is needed to confirm prior study findings. We developed an online multimodal intervention (Multiple Sclerosis Online Course) examine the impact of on pwMS via a randomized control trial (RCT). However, present specifically analyses baseline data assess engagement healthy lifestyles by RCT participants and cross-sectional associations outcomes.
Язык: Английский
Процитировано
3Neurological Sciences, Год журнала: 2024, Номер unknown
Опубликована: Окт. 21, 2024
Abstract Introduction Modifiable lifestyle risk factors for progression of multiple sclerosis (MS) have been increasingly studied. This study employed a single-group design involving one-off intensive live-in educational workshop on modification people with MS. We aimed to examine changes in range clinical and variables quality life, self-efficacy, physical impact MS disability from baseline 3- 5-years post-intervention. Methods 95 participants completed the survey. Data included diet quality, meat dairy consumption, omega 3 vitamin D supplementation, activity, stress reducing activities, smoking status, use disease-modifying therapies (DMTs). Patient-reported outcomes health-related disability. Generalised estimating equation models were used account within-participant correlation over time. Results Sixty (63.2%) provided data at 5-years. Significant improvements non-smoking seen both timepoints. Use DMTs remained unchanged. Mental (8.8- 6.9-point) (10.5- 7.3-point) self-efficacy (2.4- 1.9-point) improved significantly 5-years, respectively. Physical reduced 3-years (-3.7 points) trend towards reduction (-2.9 points; p = 0.079). Conclusions Education can lead short long-term mental wellbeing outcomes. suggest potential value as an adjunctive component standard therapy
Язык: Английский
Процитировано
1Опубликована: Апрель 18, 2024
Язык: Английский
Процитировано
0Sclerosis, Год журнала: 2024, Номер 2(3), С. 156 - 165
Опубликована: Июль 4, 2024
Emerging evidence links dietary interventions to favorable multiple sclerosis (MS) outcomes; however, for the efficacy of on functional disability remains sparse. Data from two 12-week, randomized, controlled pilot trials were pooled investigate a modified Paleolithic diet (Paleo) disability, as assessed by MS Functional Composite (MSFC), among people diagnosed with MS. Pooled baseline-referenced MSFC scores calculated nine-hole peg test (NHPT), timed 25-foot walk (T25FW), and Paced Auditory Serial Addition Test (PASAT) Z-scores. There was no significant difference in mean change between groups (
Язык: Английский
Процитировано
0Multiple Sclerosis Journal, Год журнала: 2024, Номер 30(8), С. 1056 - 1065
Опубликована: Июль 1, 2024
Background: Understanding nutrition’s role in multiple sclerosis (MS) can guide recommendations and intervention-based studies. Objective: Evaluate the association between nutrition pediatric-onset MS outcomes. Methods: Prospective longitudinal multicenter study conducted as part of US Network Pediatric centers. Predictors were collected using a food screener estimating intake various dietary groups (e.g. dairy fruits) additional calculated indices Healthy Eating Index (HEI)). Outcomes included time-from-enrollment to clinical relapse, new magnetic resonance imaging (MRI) T2 lesions, Expanded Disability Status Scale (EDSS) increase. Results: 353 children with enrolled (mean ± SD age 15.4 2.9, follow-up 3.9 2.6 years). Multivariable analysis demonstrated that increased by 50% recommended was associated relapse risk 41% (adjusted hazard ratio (HR) 1.41, 95% CI 1.07–1.86), progression 40% (1.40, 1.12–1.74). Increased fruit or vegetable above recommended, every five-point HEI increase decreased 25% (0.75, 0.60–0.95), 45% (0.55, 0.32–0.96), 15% (0.84, 0.74–0.96), respectively. No associations found EDSS. Conclusion: This work supports influence on course, particularly intake. Future prospective is required establish causation.
Язык: Английский
Процитировано
0Journal of Medical Internet Research, Год журнала: 2024, Номер 26, С. e58253 - e58253
Опубликована: Авг. 28, 2024
Background Digital health interventions increase access to multiple sclerosis (MS)–related knowledge for people living with MS; however, our understanding of factors associated engagement in web-based learning is limited. Objective This study aims examine associations between participant sociodemographic, health, and lifestyle-related characteristics the commencement completion Multiple Sclerosis Online Course (MSOC) a randomized controlled trial (RCT). Methods An intervention course was developed based on Overcoming MS Program—an evidence-based lifestyle modification program MS, standard care international website information. RCT conducted compare effectiveness versus improving outcomes MS. Participant data were collected from baseline survey. Associations MSOC completion, respectively, assessed using multivariate log-binomial regression. Results Overall, 1893 participants enrolled RCT, 45.27% (n=857) completed survey: 23.5% (n=444) 21.8% (n=413) course. Of these 857 participants, 631 (73.6%) commenced or course, 49.1% (218/444) 54.2% (224/413) respectively. University education, partnered relationship status, higher mental physical quality life 19%, 12%, 20%, 22% rates commencement, Clinically significant fatigue 10% reduction likelihood commencement. Strongest included middle older adulthood, male sex, fatigue, preexisting adherence diet program, 96%, 27%, 24%, 19% observed, whereas self-efficacy up 35% lower completion. practicing meditation (20% completion), employment Conclusions Sociodemographic clinical factors, as well important These may help guide design enhancement digital tailored Trial Registration Australian New Zealand Clinical Trials Registry ACTRN12621001605886; https://tinyurl.com/2vyve9p9 International Registered Report Identifier (IRRID) RR2-10.1186/s12883-023-03298-0
Язык: Английский
Процитировано
0Опубликована: Март 11, 2024
Язык: Английский
Процитировано
0